| . | Time . | Alpelisib concentration (ng/ml) . | BZG791 concentration (ng/ml) . |
|---|---|---|---|
| Patient 1 | |||
| First dose | 3 h after dose | 96.1 | 3.26 |
| Steady-state | 0 h before dose (Ctrough, ss) | 188 | 6.82 |
| Steady-state | 3 h after dose (Cmax, ss) | 543 | 11.6 |
| Patient 2 | |||
| First dose | 3 h after dose | 240 | 11.9 |
| Steady-state | 0 h before dose (Ctrough, ss) | 85.5 | 4.88 |
| Steady-state | 3 h after dose (Cmax, ss) | 835 | 28.8 |
| . | Time . | Alpelisib concentration (ng/ml) . | BZG791 concentration (ng/ml) . |
|---|---|---|---|
| Patient 1 | |||
| First dose | 3 h after dose | 96.1 | 3.26 |
| Steady-state | 0 h before dose (Ctrough, ss) | 188 | 6.82 |
| Steady-state | 3 h after dose (Cmax, ss) | 543 | 11.6 |
| Patient 2 | |||
| First dose | 3 h after dose | 240 | 11.9 |
| Steady-state | 0 h before dose (Ctrough, ss) | 85.5 | 4.88 |
| Steady-state | 3 h after dose (Cmax, ss) | 835 | 28.8 |
Ctrough, concentration reached by a drug immediately before the next dose is administered; ss, steady-state.